Bayer HealthCare and Janssen report positive real-world Xarelto study data

Bayer HealthCare and partner Janssen have announced new findings showing the effectiveness of their novel oral anticoagulant Xarelto in a real-world setting.

Data from the non-interventional XALIA study in patients with deep vein thrombosis and CALLISTO, a study in patients with cancer-associated thrombosis, both showed low rates of major bleeding and recurrent venous thromboembolism associated with Xarelto.

XALIA is significant as it is the first published prospective real-world study to confirm the benefit of a novel oral anticoagulant in the treatment of patients with deep vein thrombosis in routine clinical practice.

These real-world insights add to a body of evidence generated by prior pivotal clinical trial programme confirming the safety and effectiveness of Xarelto in a broad range of patients.

Dr Michael Devoy, member of the Bayer HealthCare executive committee and chief medical officer of the company, said: "At Bayer, we are committed to supporting physicians and the patients they see every day who are at risk of venous and arterial blood clots."